KRAS and head and neck squamous cell carcinoma: Strong synergism was demonstrated between trametinib and rapamycin in wild type CAL27 cells and in both KRAS and PIK3CA expressing CAL27 cells, supporting that the drug combination is effective in HNSCC cells displaying multiple genetic alterations (Figure 5A, Supplementary Figure S1B).